177Lu-FAP-2286 Treatment in Urethelial Neoplasms: Utility and Safety as a Novel Treatment.

NCT06880757 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Bladder (Urothelial, Transitional Cell) Cancer Metastatic or Unresectable

Interventions

OTHER: Radionuclide treatment with Lu-177 FAPI

Sponsor

Ankara University

Collaborators

[object Object]